Non-invasive prenatal testing (NIPT) is a non-invasive technique of determining whether a baby has chromosomal abnormalities such as Trisomy 21, Trisomy 18, and/or Trisomy 13, which can cause major issues once the baby is born. Small DNA fragments in the mother's blood are used to identify particular genetic material (genetic material that defines the makeup of the human cell and protein building blocks). Every mother's blood contains these tiny particles.
Non-invasive prenatal testing (NIPT) exams have produced sufficient data to demonstrate their effectiveness. The technique has been shown to be both effective and safe for the unborn child, and it has also been shown to help reduce the chances of premature birth and fetal abnormalities. Several nations and medical institutions, notably the United States, have embraced the method. Certain institutions, however, continue to follow strict rules, as certain research show that NIPT testing might result in false positive findings.
When the mother's blood samples are examined during in vitro fertilization, non-invasive prenatal testing (NIPT) is used to determine the fetus' DNA or genetic make-up using non-invasive techniques. These samples are then analyzed and compared to the woman's partner's sample. If they're the same, the infant is considered normal. If the match isn't positive, a doctor will perform more intrusive tests like amnion, ultrasound, chorionic villus sample, and chorionic DNA panel testing, among others.
NPT comes in two forms: one that can be done at home with the aid of home kits, and the other that requires a trip to the nearest medical institution. There are two approaches used in the exam. DNA extraction from saliva samples of pregnant women is one of these approaches. Amniotic fluid and amniotic sac samples are also collected, although saliva samples provide quicker findings.
The Pre-pregnancy, Perinephrine-based, PCOSogenetic Indicators test, also known as the PSI-POEME test, is the next non-invasive prenatal testing (NIPT) technique. The test's name merely says that it examines prenatal hormone levels. The alternative method makes use of a urine sample that is examined by a computer. In this example, the serum PCOSogenetic Indicators of a pregnant lady are measured. The information regarding the baby's gender, as well as the mother's food and lifestyle, will be used to interpret the results.
According to the new market research report “Non-Invasive Prenatal Testing Market by Instruments (Ultrasound, NGS, PCR, Microarray), Consumables, Method (FCMB, cf-DNA), Application (Trisomy, Microdeletion, Genetics, Rh factor) & End User (Hospital, Diagnostic Labs) - Global Forecast to 2021", published by MarketsandMarkets™, analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia, and the Rest of the World (RoW).Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=145607690The global non-invasive prenatal testing (NIPT) market is estimated to reach USD 7.3 billion by 2024 from USD 3.9 billion in 2019, at a CAGR of 13.5% during the forecast period.
Growth in this market is driven by the high risk of chromosomal abnormalities with increasing maternal age, growing preference for non-invasive techniques over invasive methods, improving reimbursement scenario for NIPT, and increasing awareness of NIPT.
However, a dearth of skilled professionals is restraining the growth of this market.Key Players in the Global NIPT MarketThe NIPT market is diversified and highly competitive, with a large number of players competing for market space.
The prominent players in the market are Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), GE Healthcare (US), BGI (China), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer Inc. (US), Laboratory Corporation of America Holdings (US), Natera, Inc. (US), and Yourgene Health (UK)Inquire or share your questions if any before the purchasing this report: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=145607690Growth prospects in Non Invasive Prenatal Testing (NIPT) Market :The global non-invasive prenatal testing (NIPT) market is estimated to reach USD 7.3 billion by 2024 from USD 3.9 billion in 2019, at a CAGR of 13.5% during the forecast period.
However, a dearth of skilled professionals is restraining the growth of this market.By method, the NIPT products market is segmented into ultrasound detection, biochemical screening tests, and cell-free DNA in maternal plasma tests.
The cfDNA in maternal plasma tests segment is expected to grow at the highest CAGR during the forecast period.Based on application, the non-invasive prenatal testing (NIPT) market is segmented into trisomy, microdeletion syndrome, and other applications (gender identification and the detection of monogenic disorders, Klinefelter syndrome, and Rhesus (Rh) blood type).
The study involved four major activities in estimating the current size of the global non-invasive prenatal testing market.
The next step was to validate these findings, assumptions, and sizing values with industry experts across the value chain through primary research.
[144 Pages Report] The global non-invasive prenatal testing (NIPT) market is estimated to reach USD 7.3 billion by 2024 from USD 3.9 billion in 2019, at a CAGR of 13.5% during the forecast period.Growth in this market is driven by the high risk of chromosomal abnormalities with increasing maternal age, growing preference for non-invasive techniques over invasive methods, improving reimbursement scenario for NIPT, and increasing awareness of NIPT.
However, a dearth of skilled professionals is restraining the growth of this market.Market DynamicsHigh Risk of Chromosomal Abnormalities With Increasing Maternal AgeGrowing Preference for Noninvasive Techniques Over Invasive MethodsImproving Reimbursement Scenario for NIPTPrograms Focusing on Increasing the Awareness of NIPTThe trisomy applications segment accounted for the largest share of the global NIPT market in 2018.Based on application, the non-invasive prenatal testing (NIPT) market is segmented into trisomy, microdeletion syndrome, and other applications (gender identification and the detection of monogenic disorders, Klinefelter syndrome, and Rhesus (Rh) blood type).
This segment is also estimated to grow at the highest CAGR during the forecast period.
The large share and high growth of this segment can primarily be attributed to factors such as the increasing maternal age and the rising incidence of chromosomal abnormalities.Get a sample PDF copy of the Report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=145607690By method, the NIPT products market is segmented into ultrasound detection, biochemical screening tests, and cell-free DNA in maternal plasma tests.
Global Non-Invasive Prenatal Testing (NIPT) Market Research Report: By Product Type (Devices, Consumables, Others), By Techniques (Biochemical Screening Tests, Ultrasound Detection), By Application (Trisomy, Microdeletion syndrome, Others) and By End-User (Diagnostic Laboratories, Hospitals, cell DNA screening) – Forecast to 2025Market Highlights:According to MRFR analysis, the global NIPT market is expected to register a CAGR of 12.8% during the forecast period of 2019 to 2025 and was valued at USD 3,514.765 million in 2018.NIPT plays an essential role in complex patient emergencies condition for monitoring the fetal growth and condition.
As a result of technological advancements, the global maternal mortality rate has reduced approximately less than 70 per 100,000 live births.
The NIPT has benefited resolve issues related DNA deletion and other chromosomal disorders.However, less accuracy of non-invasive prenatal testing compared to invasive prenatal testing is likely to hamper the growth of the global NIPT market during the forecast period.Several market players currently dominate the global NIPT market.
The key players are involved in product launches and strategic collaborations to strengthen their market positions.Market DriversGrowing global population.Adoption of unhealthy lifestyle habits during pregnancy.Rising awareness of non-invasive prenatal testing.Avail a Free Sample@ https://www.marketresearchfuture.com/sample_request/8371 Regional AnalysisThe market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.The Americas is anticipated to hold the largest market share owing to the increasing awareness about advanced NIPT procedures.
The non-invasive prenatal testing market is divided into the Americas has further been branched into North America and Latin America, with the North American market being divided into the US and Canada.The non-invasive prenatal testing market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
Asia-Pacific is anticipated to hold the largest market share owing to the increasing number of increasing population and rising adoption of technological advancements in developing regions.
